Page 15 - Read Online

As discussed above, nanocarriers enhanced the delivery 4. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S,
and cytotoxic activity of CSC-inhibitors. Several studies Crowley D, Bronson RT, Jacks T. Identification of bronchioalveolar
introduced active targeting strategies of nanoparticle stem cells in normal lung and lung cancer. Cell 2005;121:823-35.
surfaces to increase their specificity and cellular uptake 5. Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev
by CSCs. Lastly, researchers have been focusing on 6. Cancer 2013;13:727-38.
Chen K, Huang YH, Chen JL. Understanding and targeting cancer
nanoparticle-mediated drug combinatorial therapy. One stem cells: therapeutic implications and challenges. Acta Pharmacol
important advantage of nanocarriers is their capability Sin 2013;34:732-40.
to incorporate multiple therapeutic agents in one carrier 7. Wang J, Sullenger BA, Rich JN. Notch signaling in cancer stem
system, allowing co-delivery of cytotoxic drugs and CSC cells. Adv Exp Med Biol 2012;727:174-85.
inhibitors to simultaneously target both bulk tumor and 8. Hambardzumyan D1, Becher OJ, Rosenblum MK, Pandolfi PP,
CSCs. Patient cures will rely on the ablation of the entire Manova-Todorova K, Holland EC. PI3K pathway regulates survival
tumor. Ultimately, nanoparticle mediated combination of cancer stem cells residing in the perivascular niche following
therapy may prove to be the most successful in eradicating radiation in medulloblastoma in vivo. Genes Dev 2008;22:436-48.
whole tumors. 9. Campbell V, Copland M. Hedgehog signaling in cancer stem cells: a
focus on hematological cancers. Stem Cells Cloning 2015;8:27-38.
The CSC field is relatively new, and CSC-targeting 10. Simões BM, O’Brien CS, Eyre R, Silva A, Yu L, Sarmiento-Castro
therapeutics is in their early stages. While many A, Alférez DG, Spence K, Santiago-Gómez A, Chemi F, Acar A,
advances have been made in CSC research, many of Gandhi A, Howell A, Brennan K, Rydén L, Catalano S, Andó S, Gee
J, Ucar A, Sims AH, Marangoni E, Farnie G, Landberg G, Howell
these studies have been performed in vitro only, and none SJ, Clarke RB. Anti-estrogen resistance in human breast tumors is
are past the early clinical stages. Important factors such driven by JAG1-NOTCH4-dependent cancer stem cell activity. Cell
as effective dosages and side effects must be elucidated Rep 2015;12:1968-77.
before employing cancer treatment plans that target 11. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT,
both differentiated tumor cells and CSCs. There is need Brennan CW, Holland EC. PTEN/PI3K/Akt pathway regulates the
to improve the existing methods to precisely isolate, side population phenotype and ABCG2 activity in glioma tumor
identify and target CSCs. As mentioned, increasing stem-like cells. Cell Stem Cell 2009;4:226-35.
amount of nanomedicine have been evaluated about their 12. Bautch VL. Stem cells and the vasculature. Nat Med 2011;17:1437-43.
application potentials in CSC therapy, but only a small 13. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and
amount of them can be approved to translate to clinical metastasis of human breast carcinoma cell lines in nude mice.
treatment. With the fact that every cancer acts differently Cancer Res 1990;50:717-21.
in different patients, the development of personalized 14. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale
A, Olshen AB, Gerald WL, Massagué J. Genes that mediate breast
combinational therapies may serve as a key to successful cancer metastasis to lung. Nature 2005;436:518-24.
treatments. Furthermore, it is important to realize that the 15. Allahverdiyev AM, Bagirova M, Oztel ON, Yaman S, Abamor ES,
combination of nanomedicine and immunotherapy may Koc RC, Ates SC, Elcicek S, Baydar SY. Aldehyde Dehydrogenase:
present a novel direction which shows great potential in Cancer and Stem Cells. In: Canuto RA, editor. Dehydrogenases.
personalized cancer therapy. InTech; Rijeka, Croatia: 2012. pp. 3-28.
16. Duan JJ, Qiu W, Xu SL, Wang B, Ye XZ, Ping YF, Zhang X, Bian
Financial support and sponsorship XW, Yu SC. Strategies for isolating and enriching cancer stem cells:
This work was supported by National Institutes of well begun is half done. Stem Cells Dev 2013;22:2221-39.
Health grants (R01AI068978, R01CA170820 and 17. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri
P01CA132681), a translational acceleration grant from P, Turner CH, Goulet R Jr, Badve S, Nakshatri H. CD44+/CD24-
the Joint Center for Translational Medicine, the National breast cancer cells exhibit enhanced invasive properties: an early
Cancer Institute (P30CA014089), and a grant from step necessary for metastasis. Breast Cancer Res 2006;8:R59.
the Ming Hsieh Institute for Research on Engineering 18. Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg
S, Schulze-Osthoff K, Los M. Cancer stem cell markers in common
Medicine for Cancer.
cancers - therapeutic implications. Trends Mol Med 2008;10:450-60.
Conflicts of interests 19. Ali HR, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas
C. Cancer stem cell markers in breast cancer: pathological, clinical
There are no conflicts of interest. and prognostic significance. Breast Cancer Res 2011;6:R118.
20. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M,
REFERENCES Laino L, De Francesco F, Papaccio G. Cancer stem cells in solid
tumors: an overview and new approaches for their isolation and
1. Bonnet D, Dick JE. J. Human acute myeloid leukemia is organized characterization. FASEB J 2013;1:13-24.
as a hierarchy that originates from a primitive hematopoietic cell. 21. Greve B, Kelsch R, Spaniol K, Eich HT, Götte M. Flow cytometry in
Nat Med 1997;3:730-7. cancer stem cell analysis and separation. Cytometry A 2012;4:284-93.
2. Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M. 22. Komuro H, Saihara R, Shinya M, Takita J, Kaneko S, Kaneko
Prospective identification of tumorigenic breast cancer cells. PNAS M, Hayashi Y. Identification of side population cells (stem-like
2003;100:3983-8. cell population) in pediatric solid tumor cell lines. J Pediatr Surg
3. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire 2007;42:2040-5.
J, Dirks PB. Identification of a cancer stem cell in human brain 23. Miranda-Lorenzo I, Dorado J, Lonardo E, Alcala S, Serrano AG,
tumors. Cancer Res 2003;63:5821-8. Clausell-Tormos J, Cioffi M, Megias D, Zagorac S, Balic A,
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ July 8, 2016 ¦ 239